The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

被引：1
|
作者：
Ashcroft, John
de Tute, Ruth M.
Cairns, David A.
Fletcher, Marie
Owen, Roger G.
Rawstron, Andy
O'Connor, Sheila J. M.
Williams, Cathy D.
Snowden, John A.
Cavenagh, J. D.
Parrish, Christopher
Morris, Treen
Brown, Julia M. B.
Cook, Gordon
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3378.3378
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3378
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The utility of minimal residual disease (MRD) assessment in post-first relapse re-induction: results from the BSBMT/UKMF Myeloma X (intensive) Trial
    Owen, R. G.
    DeTute, D. M.
    Ashcroft, A. J.
    Cairns, D. A.
    Fletcher, M.
    Williams, C.
    Cavenagh, J. D.
    Snowden, J. A.
    Rawstron, A. C.
    Parrish, C.
    Morris, T. C.
    Brown, J. M. B.
    Cook, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 65 - 66
  • [2] MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT IN POST-FIRST RELAPSE RE-INDUCTION IS PREDICTIVE FOR TIME TO PROGRESSION (TTP): RESULTS FROM THE BSBMT/UKMF MULTIPLE MYELOMA (MM) X INTENSIVE TRIAL
    Ashcroft, J.
    De Tute, R. M.
    Cairns, D. A.
    Fletcher, M.
    Owen, R. G.
    Williams, C.
    Cavanagh, J. D.
    Snowden, J. A.
    Rawstron, A. C.
    Parrish, C.
    Morris, T. C. M.
    Brown, J. M. B.
    Cook, G.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S79 - S80
  • [3] BSBMT/UKMF Myeloma X Relapse (intensive) Trial - challenges in recruitment and randomisation
    Morris, T. C. M.
    Williams, C.
    Bell, S.
    Flrtcher, M.
    Szubert, A.
    Yong, K.
    Cavet, J.
    Cavenagh, J.
    Snowden, J.
    Ashcroft, J.
    Brown, J.
    Cook, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 52 - 52
  • [4] Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial
    Cook, Gordon
    Ashcroft, John
    Williams, Cathy D.
    Cairns, David A.
    Fletcher, Marie
    Parrish, Christopher
    Cavenagh, James D.
    Snowden, John A.
    O'Connor, Sheila J.
    Owen, Roger G.
    Brown, Julia
    Morris, Treen
    BLOOD, 2013, 122 (21)
  • [5] BSBMT/UKMF myeloma X relapse (intensive) trial: barriers to recruitment and randomization
    Morris, C.
    Williams, C.
    Bell, S.
    Fletcher, M.
    Szubert, A.
    Yong, K.
    Covet, J.
    Cavenagh, J.
    Snowden, J.
    Ashcroft, J.
    Brown, J.
    Cook, G.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S210 - S211
  • [6] Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
    Ruth M. de Tute
    Gordon Cook
    David A. Cairns
    Julia M. Brown
    Jamie Cavenagh
    A. John Ashcroft
    John A. Snowden
    Kwee Yong
    Eleni Tholouli
    Matthew Jenner
    Anna Hockaday
    Mark T. Drayson
    Treen C. M. Morris
    Andy C. Rawstron
    Roger G. Owen
    Bone Marrow Transplantation, 2024, 59 : 431 - 434
  • [7] Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
    de Tute, Ruth M.
    Cook, Gordon
    Cairns, David A.
    Brown, Julia M.
    Cavenagh, Jamie
    Ashcroft, A. John
    Snowden, John A.
    Yong, Kwee
    Tholouli, Eleni
    Jenner, Matthew
    Hockaday, Anna
    Drayson, Mark T.
    Morris, Treen C. M.
    Rawstron, Andy C.
    Owen, Roger G.
    BONE MARROW TRANSPLANTATION, 2024, 59 (03) : 431 - 434
  • [8] Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial
    De Tute, Ruth
    Cairns, David
    Rawstron, Andrew
    Pawlyn, Charlotte
    Davies, Faith
    Jones, John
    Kaiser, Martin
    Hockaday, Anna
    Striha, Alina
    Cook, Gordon
    Russell, Nigel
    Drayson, Mark
    Jenner, Matthew
    Gregory, Walter
    Morgan, Gareth
    Jackson, Graham
    Owen, Roger
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E45 - E46
  • [9] Superior response durability following a second autologous stem cell transplant (ASCT) for relapsed multiple myeloma (MM): results from the BSBMT/UKMF myeloma X (Intensive) trial
    Cook, G.
    Williams, C.
    Szubert, A.
    Yong, K.
    Cavet, J.
    Hunter, H.
    Bird, J.
    Bell, S.
    O'Connor, S.
    Cavenagh, J.
    Snowden, J. A.
    Parrish, C.
    Ashcroft, J.
    Brown, J.
    Morris, T. C. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 8 - 8
  • [10] Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
    Maiolino, Angelo
    Da Costa, Elaine Sobral
    Orfao, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 13
12345